3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
8
Thoracic
2
Gastrointestinal
2
Plasma cell
1
Lymphoid
1
Head & Neck
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Melanoma
3
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Merkel Cell
1
Breast Neoplasms
1
Interventions
pembrolizumab
24
Nivolumab
13
atezolizumab
7
Ipilimumab
6
Cyclophosphamide
6
fludarabine
5
Specimen Handling
5
Magnetic Resonance Spectroscopy
5
aldesleukin
4
Interleukin-2
4
Biopsy
4
durvalumab
3
cemiplimab
3
Docetaxel
3
tislelizumab
2
osimertinib
2
fludarabine phosphate
2
enzalutamide
2
avelumab
2
X-Rays
2
Ritonavir
2
Radiotherapy
2
Observation
2
Methods
2
Immunoglobulin G
2
IFL protocol
2
Drug Therapy
2
zimberelimab
1
utomilumab
1
ulixertinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
zimberelimab
×
Dermatologic
×
Clear all
NCT04772989
2025-08-28
ARC-12
Arcus Biosciences, Inc.
Phase 1
Completed
94 enrolled